

CLEAN COPY OF AMENDMENTS TO THE CLAIMS

1-11. (Canceled)

12. (Currently amended) An isolated polynucleotide encoding a T cell receptor (TCR) alpha chain portion containing three alpha complementarity determining regions (CDRs):

CDR1 α : SSYSPS (SEQ ID NO: 2);

CDR2 α : YTSAATL (SEQ ID NO: 3); and

CDR3 α : SPFSGGGADGLT (SEQ ID NO: 5),

wherein a TCR molecule containing the TCR alpha chain portion encoded by said polynucleotide and a TCR beta chain portion containing three beta CDRs:

CDR1 β : DFQATT (SEQ ID NO: 6);

CDR2 β : SNEGSKA (SEQ ID NO: 7); and

CDR3 β : RDGGESETQY (SEQ ID NO: 9)

has affinity for an HLA-A2/RMFPNAPYL (SEQ ID NO: 1) complex.

13. (Currently amended) An isolated polynucleotide encoding a T cell receptor (TCR) beta chain portion containing three beta complementarity determining regions (CDRs):

CDR1 β : DFQATT (SEQ ID NO: 6);

CDR2 β : SNEGSKA (SEQ ID NO: 7); and

CDR3 β : RDGGESETQY (SEQ ID NO: 9),

wherein a TCR molecule containing the TCR beta chain portion encoded by said polynucleotide and a TCR alpha chain portion containing three alpha CDRs:

CDR1 α : SSYSPS (SEQ ID NO: 2);

CDR2 α : YTSAATL (SEQ ID NO: 3); and

CDR3 α : SPFSGGGADGLT (SEQ ID NO: 5)

has affinity for an HLA-A2/RMFPNAPYL (SEQ ID NO: 1) complex.

14. (Currently amended) An isolated polynucleotide encoding a single chain T cell receptor (TCR) molecule containing an alpha chain portion and a beta chain portion,

wherein the alpha chain portion contains three complementarity determining regions (CDRs):

CDR1 α : SSYSPS (SEQ ID NO: 2);

CDR2 α : YTSAATL (SEQ ID NO: 3); and

CDR3 α : SPFSGGGADGLT (SEQ ID NO: 5),

and wherein the beta chain portion contains three CDRs:

CDR1 β : DFQATT (SEQ ID NO: 6);

CDR2 β : SNEGSKA (SEQ ID NO: 7); and

CDR3 β : RDGGESETQY (SEQ ID NO: 9),

wherein the TCR molecule encoded by said polynucleotide has affinity for an HLA-A2/RMFPNAPYL (SEQ ID NO: 1) complex.

15. (Previously presented) An expression vector comprising the polynucleotide according to any one of claims 12 to 14.

16. (Previously presented) The expression vector according to claim 15 which is a retroviral vector.

17. (Previously presented) A host cell comprising the polynucleotide according to any one of claims 12 to 14.

18. (Previously presented) The host cell according to claim 17 which is a T cell.

19. (Previously presented) The host cell according to claim 18 which is a T cell derived from a patient.

20-27. (Canceled)

28. (Previously presented) A host cell comprising the expression vector according to claim 15.

29. (Previously presented) The host cell according to claim 28 which is a T cell.

30. (Previously presented) The host cell according to claim 28 which is a T cell derived from a patient.

31-38. (Canceled)